Immunome (IMNM) Receives a Buy From J.P. Morgan
Wedbush Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $33
TD Cowen Maintains Immunome(IMNM.US) With Buy Rating
Immunome Is Maintained at Overweight by Piper Sandler
Piper Sandler Maintains Immunome(IMNM.US) With Buy Rating, Cuts Target Price to $21
Immunome Analyst Ratings
TD Cowen Maintains Immunome(IMNM.US) With Buy Rating
Promising Growth Potential for Immunome: Buy Rating Backed by Strategic Acquisitions and Innovative Pipeline
Stephens Initiates Immunome(IMNM.US) With Buy Rating, Announces Target Price $30
Immunome Initiated With an Overweight at Stephens on 'Seasoned Leadership'
Immunome Analyst Ratings
Wedbush Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $33
TD Cowen Maintains Immunome(IMNM.US) With Buy Rating
Wedbush Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $33
Leerink Partners Maintains Immunome(IMNM.US) With Buy Rating, Maintains Target Price $38
Buy Rating Affirmed on Immunome: Promising Clinical Trials and Strategic Growth Prospects
TD Cowen Maintains Immunome(IMNM.US) With Buy Rating
Piper Sandler Maintains Immunome(IMNM.US) With Buy Rating, Cuts Target Price to $23
Immunome Analyst Ratings
Piper Sandler Sticks to Their Buy Rating for Immunome (IMNM)